← Back to headlines
Rhythm anticipates $385M–$415M in 2026 non-GAAP operating expenses as HO launch preparations accelerate
Rhythm Pharmaceuticals expects non-GAAP operating expenses of $385 million to $415 million in 2026, as it accelerates preparations for its HO launch.
26 Feb, 20:09 — 26 Feb, 20:09
ℹOnly 1 source covers this story
